October 20, 2023
Source: Press Release, Prague
SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting a trial-in-progress poster at the European Society for Medical Oncology Congress taking place October 20-24, 2023 in Madrid, Spain.
SOTIO’s poster will present an overview of the CLAUDIO-01 Phase 1/2 study of the company’s lead antibody-drug conjugate program, SOT102. SOT102 is a potent Claudin 18.2 antibody-drug conjugate being evaluated for the treatment of gastric and pancreatic cancers.
CLAUDIO-01 (EudraCT number: 2021-005873-25) is a first-in-human, open-label, multicenter trial to assess the safety and preliminary efficacy of SOT102 in patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) or pancreatic cancers. SOTIO is progressing dose-finding studies in the trial’s monotherapy arm, in which SOT102 is used as a later-stage treatment. Additionally, SOTIO recently announced the initiation of the combination arms of the CLAUDIO-01 trial, which will provide the first clinical evaluation of SOT102’s potential as a first-line cancer treatment in combination with current standard of care.
Presentation details are as follows:
Title: “CLAUDIO-01: A multicentric phase I/II trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care (SoC) in patients with gastric, gastroesophageal junction(GEJ), and pancreatic adenocarcinoma”
Number: 722TiP
Date: Monday, October 23, 2023
Presenter: Radka Obermannova
A copy of the poster can be accessed below.
ESMO 2023 poster - CLAUDIO-01.pdf